Online inquiry

IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6039MR)

This product GTTS-WQ6039MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Giant cell arteritis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6039MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2060MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AH-PD1
GTTS-WQ6414MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CT-011
GTTS-WQ9889MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ13255MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ10162MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ9985MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KD-247
GTTS-WQ1882MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGEN1884
GTTS-WQ7860MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-2398852
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW